AlloVir, Inc. ALVR

Overview

Allovir, Inc. is a clinical-stage cell therapy company focused on pioneering the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies. These innovative treatments are designed to prevent and treat a range of devastating viral-associated diseases. Originally known as ViraCyte, Inc., the company underwent a name change to Allovir, Inc. in May 2019, marking a new chapter in its commitment to advancing cell therapy treatments. Since its inception in 2013, Allovir has been headquartered in Waltham, Massachusetts, where it continues to push the boundaries of medical research in viral disease treatment.

Products and Services

Allovir, Inc.'s product pipeline is a testament to its dedication to combating viral infections through innovative cell therapy solutions. Each product is at various stages of development, ranging from preclinical to clinical trials, and is designed to target specific viruses or groups of viruses.

• Posoleucel: This is Allovir’s lead product. An allogeneic, off-the-shelf VST therapy, posoleucel is designed to treat a spectrum of viral infections, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. By targeting these common but potentially severe viruses, posoleucel represents a significant advance in the treatment of viral-associated diseases.
• ALVR106: Directed at respiratory viruses, ALVR106 is a development candidate intended to safeguard against and treat infections from the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus. This focus on respiratory pathogens highlights Allovir’s commitment to addressing viruses with high incidence rates and significant impacts on public health.
• ALVR109: In response to the global SARS-CoV-2 (COVID-19) pandemic, ALVR109 is being developed specifically to treat infections caused by the novel coronavirus. This endeavor underscores Allovir’s agility in addressing emergent viral threats through the application of its VST therapy platform.
• ALVR107: Targeting hepatitis B, a persistent viral infection affecting the liver, ALVR107 is another of Allovir’s innovative cell therapy products in the pipeline. Through this product, the company aims to offer a new hope for patients suffering from hepatitis B, a disease with limited effective treatment options.
• ALVR108: Although specific details about ALVR108’s target indications are not described in the overview, its inclusion in Allovir’s pipeline signifies the company’s ongoing efforts to expand its range of cell therapy products to cover more viral diseases and meet unmet medical needs.